A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria

Table 4 Parasite reduction ratios in the various groups

Group	Day of treatment	Parasite density (geometric mean)	PRR	Time to 50 % parasite density (days)	Time to 90 % parasite density (days)
SCD	Day 0	1197	-		-
	Day 1	788	1.52	2	5
	Day 2	599	1.99
	Day 3	226	5.28
HbAA	Day 0	11,774	-
	Day 1	2,811	4.18	0.6	1.6
	Day 2	118	99.23
	Day 3	32	367.95
SCD-AA	Day 0	1,012	-
	Day 1	684	1.47	2.7	3
	Day 2	2,135	0.47
	Day 3	64	15.81
SCD-AL	Day 0	1,408	-
	Day 1	869	1.62	1.25	7
	Day 2	228	6.15
	Day 3	2840	0.49

SCD = sickle cell disease, HbAA = non-SCD, SCD-AA = SCD subjects treated with artesunate-amodiaquine, SCD-AL = SCD subjects treated with artemether-lumefantrine.

ISSN: 1475-2875